Project Grant W81XWH1910704

The National Cancer Institute awarded Oncotrap Inc. a $400,000 Project Grant to develop an aptamer-directed IgG1-Fc drug conjugate (AFDC) platform for the treatment of pancreatic ductal adenocarcinoma (PDAC). The project aims to validate the ability of the APTPDAC aptamer to selectively kill PDAC cells and create a potent AFDC targeting PDAC cells. Additionally, the project will evaluate the in vivo anti-tumor efficacy of the AFDC in PDAC mouse models and identify the target cell surface...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $736,168 to the Sloan-Kettering Institute for Cancer Research to develop first-in-class antibody-drug conjugates (ADCs) and payloads specifically designed for combination with external beam radiotherapy. The key products and services to be delivered include: Developing HER2-directed ADCs containing DNA damage response inhibitors as payloads, which have demonstrated efficacy in vitro and...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...

The National Cancer Institute (NCI) awarded a $215,311 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston (UTHealth) for the project "Preclinical Efficacy of GPR56 Antibody-Drug Conjugates and Combination Therapies for Triple-Negative Breast Cancer". The 24-month grant aims to develop and evaluate GPR56 antibody-drug conjugates (ADCs) as a novel targeted therapy for triple-negative breast cancer (TNBC),...

This $1,000,000 Cooperative Agreement award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of advanced antibody-drug conjugate (ADC) cancer therapies by Window Therapeutics, Inc. The project aims to create the next generation of ADCs with significantly higher drug-to-antibody ratios (30-90 drugs per antibody) compared to current industry standards. This is intended to enable the use of less toxic drugs and...

The University of California, Davis (UC Davis) was awarded a $615,399 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to develop a novel therapeutic platform for on-demand modulation of the tumor microenvironment. The project aims to utilize a transformable nanoparticle (TNP) platform that can change morphology to selectively accumulate and retain therapeutics at the tumor site, sparing normal tissues. The researchers will develop TNP constructs...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $399,966 in funding to Cloverleaf Bio, Inc. to advance the pre-clinical development of a novel therapeutic approach for treating hepatocellular carcinoma (HCC), the most common form of liver cancer. The key objectives are to: (1) develop additional in vitro-optimized therapeutic transfer RNAs (tRNAs) containing the chemotherapeutic agent 5-fluorouracil (5-FU) to target multiple...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) for $482,236 supports research to investigate methods for reverting resistance to the antibody-drug conjugate trastuzumab deruxtecan (T-DXD) in HER2-low colorectal cancer. The principal investigator at the Sloan-Kettering Institute for Cancer Research will conduct a biomarker-intensive Phase 2 clinical trial evaluating the safety and efficacy of combining T-DXD with the anti-EGFR...

This federal Project Grant award, valued at $630,171.00, was provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395). The award aims to develop a first-in-class targeted radiopharmaceutical therapy (RPT) for the treatment of triple-negative breast cancer (TNBC), which lacks effective hormonal therapies. The key product being developed is a novel variable new antigen receptor (VNAR) binding domain from a nurse shark that targets the c-Met receptor,...

This Project Grant award, titled "INVESTIGATING MITOCHONDRIAL NETWORKS AS A CRITICAL DETERMINANT OF RESPONSE TO ANTIBODY DRUG CONJUGATES IN ADVANCED NSCLC", is funded by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395). The $531,379 award, which runs from March 2025 to February 2030, aims to evaluate the role of mitochondrial networks in determining the response to antibody drug conjugates (ADCs) in advanced/metastatic non-small cell...